DUBLIN--(BUSINESS WIRE)--The "Huntington's Disease Market Analysis by Treatment (Disease-modifying Therapies, Symptomatic Treatment) and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
The Hutington's Disease market size is estimated to be USD 475.3 million in 2021 and is expected to witness a CAGR of 21.61% during the forecast period 2022-2029.
Ingrezza's expected label expansion for treating chorea associated with Huntington's disease, the high prevalence of HD in Western countries, and a robust product pipeline of disease-modifying treatments is expected to drive the market. However, low success rate in clinical trials is expected to restrain the market growth.
Segmentation: Hutington's Disease Market Report 2021-2029
By Treatment (Revenue, USD Million)
- Disease-modifying Therapies
- Symptomatic Treatment
By Region (Revenue, USD Million)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Companies Mentioned
- Teva (Israel)
- Novartis AG (Switzerland)
- GSK (UK)
- AbbVie (US)
- Merck (US)
- Boehringer Ingelheim (Germany)
- Impax Laboratories (US)
- Lundbeck (Denmark)
- UCB (Belgium)
- Valeant Pharmaceuticals (Canada)
- Acadia (US)
- Sun Pharma (India)
- Wockhardt (India)
- Dr. Reddy's (India)
- Intas (India)
- US WorldMeds (US)
- Zydus Cadila (India)
- Cipla (India)
- Strides (India)
- 1 A Pharma (India)
- Upsher-Smith (US)
For more information about this report visit https://www.researchandmarkets.com/r/aboj38
